Clinical Trials Logo

Clinical Trial Summary

This clinical validation study is aimed at testing the efficacy of a new environmental challenge chamber (ECC) to induce symptoms of allergic rhinitis in patients allergic to house dust mite. The symptoms will be recorded on a validated symptom score as Total Nasal Symptom Score (TNSS), allowing for determine whether the challenge is dose dependent and reproducible.


Clinical Trial Description

At Fraunhofer ITEM, a novel technique to create an atmosphere loaded with allergenic particles was recently developed. In brief, particles are produced in a combined process of nebulization and drying of a solution containing soluble allergenic extracts and lactose. The particle size distribution is regulated by the droplet size distribution and the lactose concentration in the solution, while the allergen content can be chosen independently. Thus, the Fraunhofer scientists have created a universal tool which provides them with the possibility to create atmospheres containing allergenic particles of arbitrary sizes containing a variety of different allergens. By choosing particle sizes preferentially depositing in the nose (above 10 µm) or the lungs (5 to 10 µm), and selecting allergen concentrations commonly found in the environment, it is possible to build up challenge atmospheres for a large variety of indications.

The first clinical application of this new method will be to create an atmosphere simulating the natural exposure to house dust mite allergens. The challenge aerosol will be composed of lactose as carrier material and the two major allergens Der p1 and Der p2 of house dust mites originating from a licenced allergen extract for inhaled challenge. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science


Related Conditions & MeSH terms


NCT number NCT01275456
Study type Interventional
Source Fraunhofer-Institute of Toxicology and Experimental Medicine
Contact
Status Completed
Phase N/A
Start date January 2011
Completion date May 2011

See also
  Status Clinical Trial Phase
Recruiting NCT04109534 - Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma N/A
Not yet recruiting NCT05641272 - Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract Phase 2/Phase 3
Completed NCT04969653 - The Incidence of Venous Thromboembolism in Atopic Dermatitis
Completed NCT04673591 - Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients Phase 2
Withdrawn NCT01019291 - Role of Indoor Pollutants on House Dust Mite Allergic Asthma N/A